Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 31-37

  Lasek, Witold ^a   Wańkowicz, Anna ^a   Kuc, Katarzyna ^a   Feleszko, Wojciech ^a   Giermasz, Adam ^a   Jakóbisiak, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Actinomycin D; Interferon gamma; Melanoma; Mouse model; Tumor necrosis factor alpha

Indexed keywords

ANTINEOPLASTIC AGENT; DACTINOMYCIN; GAMMA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; INTRATUMORAL DRUG ADMINISTRATION; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON TYPE II; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030046493     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227531     Document Type: Article

References (33)

1. Creasey AA, Doyle LV, Reynolds MT, Jung T, Lin LS, Vitt CR: Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res 1987;47:145-149.
2. Sugarman BJ, Aggarwal BB, Hass PE. Figari IS. Palladino MA Jr. Shepard HM: Recombinant human tumor necrosis factor-a: Effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943-945.
3. Schiller JH, Witt PL, Storer B, Alberti D, Tornbes MB, Arzoomanian R, Brown RR, Proctor RA, Voss SD, Spriggs DR, Trump DL, Borden EC: Clinical and biologic effects of combination therapy with gamma-inlcrferon and tumor necrosis factor. Cancer 1992:69: 562-571.
4. Hieber U, Heim ME: Tumor necrosis factor for the treatment of malignancies. Oncology 1994: 51:142-153.
5. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA. Tavernier J. Ficrs W: Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986:46: 3990-3993.
6. Brouekaert PGG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W: In vivo antitumour activity of recombinant human and murine TNF. alone and in combination with murine IF'N-y, on a syngeneic murine melanoma. Int J Cancer 1986:38:763-769.
7. Chen L, Suzuki Y, Wheelock EF: Intcferon-y synergizcs with tumor necrosis factor and with interleukin 1 and requires the presence of both monokines to induce antitumor cytotoxic activity in macrophages. J Immunol 1987:139: 4096-4101.
8. Fransen L, Van Der Heyden J, Ruysschaerl R, Fids W: Recombinant tumor necrosis factor: Its effect and its synergism with intcrferon-y on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986:22: 419-426.
9. Owen-Schaub LB, Santee SM, Winkelhakc JL, Zimmerman RJ: Role of tumor necrosis factor species in the sequence-dependent effects of interleukin-2-tumor necrosis factor immunotherapy in mice: Implications for preclinical cytokine testing. J Immunother 1994:15:1-10.
10. Winkelhakc JL, Stampfl S, Zimmerman RI: Synergistic effects of combination therapy with human recombinant intcrleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res 1987;47:3948-3953.
11. Alexander RB, Nelson WG, Coffey DS: Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987:47:2403-2406.
12. Krosnick JA, Mule JJ, McIntosh JK, Rosenberg SA: Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 1989;49:3729-3733.
13. Krcuser E-D, Wadler S, Thiel E: Interactions between cytokines and cytotoxic drugs: Putative molecular mechanisms in experimental hematology and oncology. Semin Oncol 1992:19: 1-7.
14. Srinivasan JM, Fajardo LF, Hahn GM: Mechanism of antitumor activity of tumor necrosis factor a with hyperthermia in a tumor necrosis factor a-resislant tumor. J Natl Cancer Inst 1990;82:1904-1910.
15. Eggcrmont AMM, Lienard D, Koops HS, Rosenkaimer F, Lejeune FJ: Treatment of irre-sectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNFa in combination with inlerferon-y and melphaian; in Fiers W, Buurman WA (eds): Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Basel. Kargcr. 1993. pp 239-243.
16. 7 or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon. and melphaian. Cancer 1994:73:483-492.
17. Utsugi T, Mattern MR, Mirabelli CK, Hanna N: Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: Enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 1990:50:2636-2640.
18. Hori K, Elirke MJ, Mace K, Maccubbin D, Doyle MJ, Otsuka Y, Mihich E: Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumori-cidal activity. Cancer Res 1987;47:2793-2798.
19. Philip R, Epstein LB: Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, y-interferon and interleukin-1. Nature 1986;323:86-89.
20. Talmadgc JE, Philips H, Schneider M, Rowe T, Pennington R, Bowersox O, Lenz B: immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988;48:544-550.
21. Pak AS, Ip G, Wright MA, Young MRI: Treating tumor-bearing mice with low-dose y-inter-feron plus tumor necrosis factor a to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res 1995: 55:885-890.
22. Lasek W, Wankowiez A, Kuc K, Feleszko W, Gotab J, Giermasz A, Wiktor-Jedrzejczak W. Jakobisiak M: Potentiation of antitumor effects of tumor necrosis factor a and interferon y by macrophagc-colony-stimulating factor in a MmB16 melanoma model in mice. Cancer Immunol Immunother 1995;40:315-321.
23. Heaton KM, Grimm EA: Cytokine combination in immunotherapy for solid tumors: A review. Cancer Immunol Immunother 1993; 37:213-219.
24. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-745.
25. Naume B, Shalaby R, Lesslauer W, Espevik T: Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lym-phokine-activated killer cell activity and proliferation of natural killer cells. J Immunol 1991; 146:3045-3048.
26. Chabner BA, Myers CE: Clinical pharmacology of cancer chemotherapy: in DeVita VT Jr. Heilman S, Rosenberg SA (eds): Cancer - Principles and Practice of Oncology. Philadelphia, Lippincott. 1989. pp 349-395.
27. Alexander RB, Isaacs JT, Coffey DS: Tumor necros;s factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer. J Urol 1987: 138:427-429.
28. Bahnson RR, Ratliff TL: In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor(MBT-2). J Urol 1990:144:172-175.
29. Seibel ML, Dinndorf PA, Bauer M. Sondel PM, Hammond GD, Reaman GH: Phase 1 study of tumor necrosis factor-u and actinomycin D in pediatric patients with cancer: A children’s cancer group study. J Immunother 1994:16: 125-131.
30. Munker R, Gasson J, Ogawa M, Koeffler HP: Recombinant human tumor necrosis factor induces production of granulocyte monocyte colony-stimulating factor. Nature 1986:323:816-818.
31. Urbaschek R, Mannel DN, Urbaschek B: Tumor necrosis factor induced stimulation of granulopoiesis and radioprotection. Lvmphok Res 1987;6:179-186.
32. Lasck W, Sora M, Wankowiez A, Jakobisiak M: Combination of immunotherapy with cy-clophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice. Cancer Lett 1995:89:137-143.
33. Sparano JA, Wadler S, Liebes L, Robert NJ, Schwartz EL, Dutcher JP: Phase 1 trial of cyclophosphamide. doxorubicin, and 5-fluorouracil plus interferon-a2b in patients with advanced breast cancer. Cancer Res 1993:53:3509-3512.